{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:53:30Z","timestamp":1785855210599,"version":"3.56.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Canadian Network Undertaking against Hepatitis C"},{"name":"Gilead and AbbVie"},{"name":"Canadian Network on Hepatitis C"},{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immigrants to Canada are disproportionately affected by hepatitis C virus (HCV) infection. Little is known about treatment outcomes among immigrants at the national level or how outcomes vary across Canadian provinces.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used data from the Canadian Network Undertaking against Hepatitis C (CANUHC), a prospective cohort enrolling HCV RNA\u2013positive patients from 17 sites across 6 Canadian provinces between 2015 and 2025. Sociodemographic data, clinical characteristics, immigration details, time to first consult, and treatment outcomes were evaluated. Treatment outcomes included direct-acting antiviral (DAA) initiation, sustained virological response (SVR) bloodwork completion, and SVR achievement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 2521 patients, 427 (16.9%) were immigrants to Canada. Immigrants had higher educational attainment (60.8% vs 28.2% college\/university, P &amp;lt; .001), higher employment (47.1% vs 28.0%, P &amp;lt; .001), and lower proportions with a history of injection drug use (25.8% vs 75.3%, P &amp;lt; .001), incarceration (12.9% vs 49.1%, P &amp;lt; .001), or recreational drug use (43.5% vs 91.8%, P &amp;lt; .001). Immigrants demonstrated excellent DAA treatment outcomes with higher crude rates of DAA initiation (95.6% vs 92.2%, P = .02), posttreatment SVR bloodwork completion (81.6% vs 70.5%, P &amp;lt; .001), and SVR (100% vs 98.6%, P = .03). However, after adjustment for age, sex, race, and key socioeconomic measures, immigration status was not independently associated with these outcomes. The mean time from immigration to specialist assessment was 24.9 years (standard deviation, 18.6 years). The delay in accessing care trended downward with each 5-year interval from 1990 to the present (median years, 26, 22, 16, 12, 7, and 2; P &amp;lt; .001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Immigrants in the CANUHC cohort achieved excellent DAA treatment outcomes comparable to or exceeding those of Canadian-born patients. When engaged in care, immigrants can successfully complete the HCV treatment cascade.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag461","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:29:31Z","timestamp":1784633371000},"source":"Crossref","is-referenced-by-count":0,"title":["Hepatitis C Treatment Outcomes Among Immigrants: A CANUHC Cohort Analysis"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1403-7070","authenticated-orcid":false,"given":"Haris","family":"Imsirovic","sequence":"first","affiliation":[{"name":"Ottawa Hospital Research Institute , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1405-0022","authenticated-orcid":false,"given":"Sabrina","family":"Fan","sequence":"additional","affiliation":[{"name":"University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8576-5082","authenticated-orcid":false,"given":"Gisela","family":"Macphail","sequence":"additional","affiliation":[{"name":"University of Calgary , Calgary, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Webster","sequence":"additional","affiliation":[{"name":"Dalhousie University , Halifax, Nova Scotia ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Smyth","sequence":"additional","affiliation":[{"name":"Dalhousie University , Halifax, Nova Scotia ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Borgia","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, William Osler Health System , Brampton, Ontario ,","place":["Canada"]},{"name":"Division of Infectious Diseases, McMaster University , Hamilton, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2211","authenticated-orcid":false,"given":"Jordan J","family":"Feld","sequence":"additional","affiliation":[{"name":"Toronto Centre for Liver Disease, University Health Network, University of Toronto , Toronto, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Calgary , Calgary, Alberta ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3368-3499","authenticated-orcid":false,"given":"Curtis L","family":"Cooper","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute , Ottawa, Ontario ,","place":["Canada"]},{"name":"University of Ottawa , Ottawa, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026080410182556600_ofag461-B1","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3961\/jpmph.21.151","article-title":"Trends of the global hepatitis C disease burden: strategies to achieve elimination","volume":"54","author":"Brunner","year":"2021","journal-title":"J Prev Med Public Health"},{"key":"2026080410182556600_ofag461-B2","author":"World Health Organization"},{"key":"2026080410182556600_ofag461-B3","author":"World Health Organization"},{"key":"2026080410182556600_ofag461-B4","author":"Statistics Canada"},{"key":"2026080410182556600_ofag461-B5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3138\/canlivj.1.2.004","article-title":"Addressing hepatitis C in the foreign-born population: a key to hepatitis C virus elimination in Canada","volume":"1","author":"Greenaway","year":"2018","journal-title":"Can Liver J"},{"key":"2026080410182556600_ofag461-B6","author":"Statistics Canada"},{"key":"2026080410182556600_ofag461-B7","first-page":"493","article-title":"Timing of elimination of hepatitis C virus in Canada's provinces","volume":"5","author":"Feld","year":"2022","journal-title":"Can Liver J"},{"key":"2026080410182556600_ofag461-B8","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1365-2893.2012.01583.x","article-title":"Immigrant patients with chronic hepatitis C and advanced fibrosis have a higher risk of hepatocellular carcinoma","volume":"19","author":"Chen","year":"2012","journal-title":"J Viral Hepat"},{"key":"2026080410182556600_ofag461-B9","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/cid\/ciw540","article-title":"Hospitalizations in immigrants and nonimmigrants diagnosed with chronic hepatitis C infection in Quebec","volume":"63","author":"Kamstra","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026080410182556600_ofag461-B10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.14745\/ccdr.v51i67a01","article-title":"Estimated prevalence of hepatitis B and C among immigrants in Canada","volume":"51","author":"Campeau","year":"2025","journal-title":"Can Commun Dis Rep"},{"key":"2026080410182556600_ofag461-B11","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1186\/s12889-020-09464-0","article-title":"Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants","volume":"20","author":"Cooper","year":"2020","journal-title":"BMC Public Health"},{"key":"2026080410182556600_ofag461-B12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3138\/canlivj-2021-0037","article-title":"Uptake and factors associated with direct-acting antiviral therapy for hepatitis C and treatment outcomes among Canadian immigrants: a retrospective cohort analysis","volume":"5","author":"Petrosyan","year":"2022","journal-title":"Can Liver J"},{"key":"2026080410182556600_ofag461-B13","doi-asserted-by":"crossref","first-page":"720","DOI":"10.5604\/01.3001.0010.2714","article-title":"Hepatitis C virus infection outcomes among immigrants to Canada: a retrospective cohort analysis","volume":"16","author":"Cooper","year":"2017","journal-title":"Ann Hepatol"},{"key":"2026080410182556600_ofag461-B14","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12879-017-2242-y","article-title":"A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada","volume":"17","author":"Greenaway","year":"2017","journal-title":"BMC Infect Dis"},{"key":"2026080410182556600_ofag461-B15","author":"World Health Organization"},{"key":"2026080410182556600_ofag461-B16","author":"World Health Organization"},{"key":"2026080410182556600_ofag461-B17","doi-asserted-by":"crossref","first-page":"540","DOI":"10.14745\/ccdr.v48i1112a07","article-title":"National hepatitis C estimates: incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019","volume":"48","author":"Popovic","year":"2022","journal-title":"Can Commun Dis Rep"},{"key":"2026080410182556600_ofag461-B18","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s10903-015-0276-z","article-title":"Barriers to access of primary healthcare by immigrant populations in Canada: a literature review","volume":"18","author":"Ahmed","year":"2015","journal-title":"J Immigr Minor Health"},{"key":"2026080410182556600_ofag461-B19","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.70112","article-title":"Time to hepatitis C care engagement and treatment outcomes in Canadian immigrants have markedly improved over three decades","volume":"33","author":"Fan","year":"2026","journal-title":"J Viral Hepat"},{"key":"2026080410182556600_ofag461-B20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3138\/canlivj-2022-0040","article-title":"Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: a descriptive study","volume":"6","author":"Snell","year":"2023","journal-title":"Can Liver J"},{"key":"2026080410182556600_ofag461-B21","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3389\/fpubh.2019.00362","article-title":"Disparities in hepatitis C linkage to care in the direct acting antiviral era: findings from a referral clinic with an embedded nurse navigator model","volume":"7","author":"Sherbuk","year":"2019","journal-title":"Front Public Health"},{"key":"2026080410182556600_ofag461-B22","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3138\/canlivj.2019-0002","article-title":"Hepatitis C models of care: approaches to elimination","volume":"3","author":"Biondi","year":"2020","journal-title":"Can Liver J"},{"key":"2026080410182556600_ofag461-B23","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.3390\/ijerph19074158","article-title":"Key role of multidisciplinary collaboration towards global elimination of HCV infection","volume":"19","author":"Krekulova","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2026080410182556600_ofag461-B24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s40506-018-0177-5","article-title":"Building a hepatitis C clinical program: strategies to optimize outcomes","volume":"10","author":"Zuckerman","year":"2018","journal-title":"Curr Treat Options Infect Dis"},{"key":"2026080410182556600_ofag461-B25","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/jvh.13685","article-title":"Closing the hepatitis C treatment gap: United States strategies to improve retention in care","volume":"29","author":"Jones","year":"2022","journal-title":"J Viral Hepat"},{"key":"2026080410182556600_ofag461-B26","first-page":"459","article-title":"Identification and linkage to care of HCV-infected persons in five health centers\u2014Philadelphia, Pennsylvania, 2012\u20132014","volume":"64","author":"Coyle","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026080410182556600_ofag461-B27","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1177\/00333549211015664","article-title":"Outcomes of a pharmacist-led hepatitis C virus treatment program in an urban safety-net health system, Chicago, 2017\u20132019","volume":"137","author":"Hunt","year":"2022","journal-title":"Public Health Rep"},{"key":"2026080410182556600_ofag461-B28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.drugpo.2019.05.023","article-title":"Integrated models of care for people who inject drugs and live with hepatitis C virus: a systematic review","volume":"72","author":"Socias","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2026080410182556600_ofag461-B29","author":"Ontario HIV Treatment Network Rapid Response"},{"key":"2026080410182556600_ofag461-B30","doi-asserted-by":"crossref","first-page":"637","DOI":"10.7326\/M16-2575","article-title":"Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review","volume":"166","author":"Falade-Nwulia","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026080410182556600_ofag461-B31","volume-title":"Introduction of new hepatitis C antivirals: case for public funding in Canada","author":"Public Health Agency of Canada","year":"2017"},{"key":"2026080410182556600_ofag461-B32","volume-title":"Hepatitis C elimination in Canada: a roadmap to 2030","author":"Canadian Network on Hepatitis C","year":"2023"},{"key":"2026080410182556600_ofag461-B33","volume-title":"Eliminating hepatitis C virus: guidance for achieving the elimination agenda by 2030","author":"World Health Organization","year":"2021"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag461\/69884462\/ofag461.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/8\/ofag461\/69884462\/ofag461.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/8\/ofag461\/69884462\/ofag461.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:31:21Z","timestamp":1785853881000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag461\/8740708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag461","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,23]]},"article-number":"ofag461"}}